Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
20,901 results
  • Characterisation of blood microbiota in patients with liver cirrhosis. [Journal Article]
    Eur J Gastroenterol Hepatol 2019Kajihara M, Koido S, … Ohkusa T
  • CONCLUSIONS: The present study has demonstrated that various circulating bacteria are present in cirrhotic patients, and the diversity of such bacteria is consistent with the presence of dysbiosis in cirrhotics. Although the clinical significance of the findings remains to be clarified, the findings may potentially facilitate diagnostic and therapeutic attempts to comprehend and furthermore to manipulate bacterial infections in cirrhotic patients.
  • Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease. [Journal Article]
    Aging Dis 2019; 10(4):684-698Maeso-Díaz R, Ortega-Ribera M, … Gracia-Sancho J
  • Advanced chronic liver disease (aCLD) represents a major public health concern. aCLD is more prevalent and severe in the elderly, carrying a higher risk of decompensation. We aimed at understanding how aging may impact on the pathophysiology of aCLD in aged rats and humans and secondly, at evaluating simvastatin as a therapeutic option in aged animals. aCLD was induced in young (1 month) and old …
  • Nodular Regenerative Hyperplasia Associated With Primary Liver Malignancies. [Journal Article]
    Hepatology 2019Penrice D, Simonetto DA
  • Nodular Regenerative Hyperplasia (NRH) is histopathologic condition that may lead to the development of non-cirrhotic portal hypertension. This condition is characterized by regeneration of hepatocyte nodules in the absence of advanced liver fibrosis.1 NRH has been traditionally considered a benign process, with only two cases previously reported of NRH predating the development of hepatocellular…
  • Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis. [Journal Article]
    Sci Rep 2019; 9(1):12000Horvath A, Rainer F, … Stadlbauer V
  • Proton pump inhibitors (PPI) are an invaluable therapy option for acid related diseases; however, PPI therapy is also linked to a series of side effects in cirrhosis, such as microbiome alterations, spontaneous bacterial peritonitis and hepatic encephalopathy. Decision tools to balance benefits and risks of PPI therapy are largely missing. In this study, we tested gut-derived biomarkers to identi…
New Search Next